Novel treatments schizophrenia: Targeting the neurotensin system

B. Kinkead; C. B. Nemeroff

doi:10.2174/187152706776359655

Novel treatments schizophrenia: Targeting the neurotensin system

B. Kinkead, C. B. Nemeroff

Research output: Contribution to journal › Review article › peer-review

37 Scopus citations

Abstract

Evidence implicating neural circuits that utilize the neuropeptide transmitter neurotensin (NT) in the pathophysiology of schizophrenia and in the mechanism of action of antipsychotic drugs has previously been reviewed. The majority of evidence, taken together, supports the development of NT receptor agonists as novel antipsychotic drugs. This review comprehensively describes the NT receptor subtypes, discusses the development of NT receptor agonists and the behavioral effects of currently available NT receptor agonists. The compilation of data suggests that NT receptor agonists may represent a novel class of antipsychotic drugs for the treatment of schizophrenia.

Original language	English (US)
Pages (from-to)	205-218
Number of pages	14
Journal	CNS and Neurological Disorders - Drug Targets
Volume	5
Issue number	2
DOIs	https://doi.org/10.2174/187152706776359655
State	Published - Apr 1 2006
Externally published	Yes

Keywords

Antipsychotic drug
Neuromedin N
Peptide
Schizophrenia
Xenin

ASJC Scopus subject areas

Neuroscience(all)
Pharmacology

Access to Document

10.2174/187152706776359655

Fingerprint Dive into the research topics of 'Novel treatments schizophrenia: Targeting the neurotensin system'. Together they form a unique fingerprint.

Cite this

@article{094d43acda4c41c38f0a00a0c3ff090b,

title = "Novel treatments schizophrenia: Targeting the neurotensin system",

abstract = "Evidence implicating neural circuits that utilize the neuropeptide transmitter neurotensin (NT) in the pathophysiology of schizophrenia and in the mechanism of action of antipsychotic drugs has previously been reviewed. The majority of evidence, taken together, supports the development of NT receptor agonists as novel antipsychotic drugs. This review comprehensively describes the NT receptor subtypes, discusses the development of NT receptor agonists and the behavioral effects of currently available NT receptor agonists. The compilation of data suggests that NT receptor agonists may represent a novel class of antipsychotic drugs for the treatment of schizophrenia.",

keywords = "Antipsychotic drug, Neuromedin N, Peptide, Schizophrenia, Xenin",

author = "B. Kinkead and Nemeroff, {C. B.}",

year = "2006",

month = apr,

day = "1",

doi = "10.2174/187152706776359655",

language = "English (US)",

volume = "5",

pages = "205--218",

journal = "CNS and Neurological Disorders - Drug Targets",

issn = "1871-5273",

publisher = "Bentham Science Publishers B.V.",

number = "2",

}

TY - JOUR

T1 - Novel treatments schizophrenia

T2 - Targeting the neurotensin system

AU - Kinkead, B.

AU - Nemeroff, C. B.

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Evidence implicating neural circuits that utilize the neuropeptide transmitter neurotensin (NT) in the pathophysiology of schizophrenia and in the mechanism of action of antipsychotic drugs has previously been reviewed. The majority of evidence, taken together, supports the development of NT receptor agonists as novel antipsychotic drugs. This review comprehensively describes the NT receptor subtypes, discusses the development of NT receptor agonists and the behavioral effects of currently available NT receptor agonists. The compilation of data suggests that NT receptor agonists may represent a novel class of antipsychotic drugs for the treatment of schizophrenia.

AB - Evidence implicating neural circuits that utilize the neuropeptide transmitter neurotensin (NT) in the pathophysiology of schizophrenia and in the mechanism of action of antipsychotic drugs has previously been reviewed. The majority of evidence, taken together, supports the development of NT receptor agonists as novel antipsychotic drugs. This review comprehensively describes the NT receptor subtypes, discusses the development of NT receptor agonists and the behavioral effects of currently available NT receptor agonists. The compilation of data suggests that NT receptor agonists may represent a novel class of antipsychotic drugs for the treatment of schizophrenia.

KW - Antipsychotic drug

KW - Neuromedin N

KW - Peptide

KW - Schizophrenia

KW - Xenin

UR - http://www.scopus.com/inward/record.url?scp=33744455990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744455990&partnerID=8YFLogxK

U2 - 10.2174/187152706776359655

DO - 10.2174/187152706776359655

M3 - Review article

C2 - 16611093

AN - SCOPUS:33744455990

VL - 5

SP - 205

EP - 218

JO - CNS and Neurological Disorders - Drug Targets

JF - CNS and Neurological Disorders - Drug Targets

SN - 1871-5273

IS - 2

ER -

Novel treatments schizophrenia: Targeting the neurotensin system

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this